K-111
K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome.
For research use only. We do not sell to patients.
- CAS No.: 221564-97-2
- Formula: C18H25Cl3O2
- Molecular Weight:379.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
CAS No. 221564-97-2
-
Molecular Weight 379.75
-
Formula C18H25Cl3O2
-
SMILES
O=C(C(Cl)(CCCCCCCCCCC1=CC=C(C=C1)Cl)Cl)O
-
Synonyms
BM 17.0744
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Schäfer SA, et al. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates. Biochem Pharmacol. 2004;68(2):239-251. [Content Brief]
[2]. Ortmeyer HK, et al. Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-alpha agonist (K-111) administration in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1509-R1517. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
K-111 Related Classifications
HY-120943 Related Classifications
Powered by Bioz
- K-111
- 221564-97-2
- BM 17.0744
- K111
- K 111
- PPAR
- K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance
- reducing body weight
- and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes
- dyslipidaemia
- obesity and the metabolic syndrome[1][2].
- Inhibitor
- inhibitor
- inhibit